Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-2.77%	-7.06%	-17.85%	-71.05%	20.78M
LONZA GROUP AG	+0.68%	-2.28%	+1.91%	+19.70%	48.42B
REVOLUTION MEDICINES, INC.	+5.53%	+3.82%	+489.52%	+633.63%	43.66B
BEONE MEDICINES AG	+3.71%	+0.48%	+12.97%	+87.60%	39.51B
IQVIA HOLDINGS INC.	+1.58%	-0.88%	+24.57%	+11.97%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	+0.03%	-2.72%	-	-	16.32B
MEDPACE HOLDINGS, INC.	+2.46%	-1.59%	+28.08%	+133.79%	16.15B
EUROFINS SCIENTIFIC SE	-0.62%	-0.06%	+3.95%	+27.74%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.82%	+3.97%	+83.46%	+44.09%	13.37B
Average	+1.30%	-1.15%	+71.91%	+105.07%	26.32B
Weighted average by Cap.	+2.05%	-0.62%	+102.22%	+152.26%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
18/08/26	SEK 0.9480	-2.77%	800,829
14/08/26	SEK 0.9750	-2.69%	1,335,012
13/08/26	SEK 1.002	+8.68%	1,390,873
12/08/26	SEK 0.9220	-8.53%	2,339,356
11/08/26	SEK 1.008	-1.18%	1,241,433

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm 00:00:00 18/08/2026 HKT			5-day change	1st Jan Change
0.9480 ^SEK	-2.77%		-7.06%	+14.35%

Market Cap	198M 20.81M 17.97M 16.85M 15.35M 28.86M 1.99B 29.26M 77.42M 997M 78.13M 76.44M 3.32B	P/E 2026 *	-3.61x	P/E 2027 *	-2.57x
Enterprise Value	182M 19.12M 16.51M 15.49M 14.11M 26.53M 1.83B 26.89M 71.15M 916M 71.8M 70.25M 3.05B	EV / Sales 2026 *	5.79x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	-2.77%
1 week	-7.06%
Current month	-18.28%
1 month	+41.70%
3 months	+115.70%
6 months	+33.33%
Current year	+14.35%

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.91	1.06
1 month	0.61	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.3M 2.85M 2.67M 2.44M 4.58M 316M 4.64M 12.28M 158M 12.4M 12.13M 526M	-
Net income	-3.2M -337K -291K -273K -249K -468K -32.23M -474K -1.25M -16.15M -1.27M -1.24M -53.71M	-50.35M -5.3M -4.58M -4.3M -3.91M -7.36M -507M -7.46M -19.73M -254M -19.91M -19.48M -845M
Net Debt	-16M -1.69M -1.45M -1.36M -1.24M -2.34M -161M -2.37M -6.27M -80.73M -6.33M -6.19M -269M	-19M -2M -1.73M -1.62M -1.48M -2.78M -191M -2.81M -7.45M -95.86M -7.51M -7.35M -319M